BHB
NVO

Bank Hapoalim BM’s Novo Nordisk NVO Stock Holding History

Bank Hapoalim BM’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.16M Buy
65,863
+1,868
+3% +$80.3K 0.21% 41
2026
Q1 		$2.35M Buy
63,995
+6,425
+11% +$304K 0.36% 41
2025
Q4 		$2.93M Buy
57,570
+24,940
+76% +$1.28M 0.25% 46
2025
Q3 		$1.81M Buy
32,630
+4,880
+18% +$286K 0.22% 58
2025
Q2 		$1.92M Buy
27,750
+5,215
+23% +$355K 0.26% 59
2025
Q1 		$1.56M Buy
22,535
+13,925
+162% +$1.15M 0.23% 62
2024
Q4 		$741K Sell
8,610
-500
-5% -$54.1K 0.12% 84
2024
Q3 		$1.08M Sell
9,110
-600
-6% -$80K 0.16% 76
2024
Q2 		$1.39M Sell
9,710
-500
-5% -$66.3K 0.2% 78
2024
Q1 		$1.31M Sell
10,210
-1,350
-12% -$161K 0.17% 80
2023
Q4 		$1.2M Sell
11,560
-2,700
-19% -$267K 0.16% 82
2023
Q3 		$1.3M Sell
14,260
-1,200
-8% -$106K 0.21% 77
2023
Q2 		$1.25M Sell
15,460
-1,500
-9% -$123K 0.18% 87
2023
Q1 		$1.35M Sell
16,960
-2,680
-14% -$190K 0.19% 88
2022
Q4 		$1.33M Hold
19,640
– – 0.17% 81
2022
Q3 		$978K Sell
19,640
-400
-2% -$21.4K 0.12% 104
2022
Q2 		$1.12M Hold
20,040
– – 0.14% 104
2022
Q1 		$1.11M Sell
20,040
-4,300
-18% -$221K 0.12% 121
2021
Q4 		$1.36M Hold
24,340
– – 0.14% 113
2021
Q3 		$1.17M Hold
24,340
– – 0.12% 119
2021
Q2 		$1.02M Hold
24,340
– – 0.12% 126
2021
Q1 		$821K Hold
24,340
– – 0.1% 129
2020
Q4 		$850K Sell
24,340
-1,400
-5% -$48.4K 0.12% 108
2020
Q3 		$894 Sell
25,740
-2,600
-9% -$86.7K 0.04% 87
2020
Q2 		$928K Hold
28,340
– – 0.22% 81
2020
Q1 		$853K Hold
28,340
– – 0.27% 72
2019
Q4 		$820K Buy
28,340
+2,500
+10% +$69.2K 0.18% 80
2019
Q3 		$667K Hold
25,840
– – 0.16% 85
2019
Q2 		$659K Hold
25,840
– – 0.16% 90
2019
Q1 		$676K Hold
25,840
– – 0.16% 87
2018
Q4 		$595K Hold
25,840
– – 0.19% 85
2018
Q3 		$609K Hold
25,840
– – 0.15% 110
2018
Q2 		$596K Hold
25,840
– – 0.16% 109
2018
Q1 		$636K Hold
25,840
– – 0.16% 105
2017
Q4 		$693 Hold
25,840
– – 0.15% 106
2017
Q3 		$622K Buy
25,840
+15,000
+138% +$339K 0.14% 125
2017
Q2 		$232K Buy
+10,840
New +$219K 0.06% 186

Other funds holding NVO

Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
EHC
Everett Harris & Co Los Angeles, California $8.14B AUM 14.79% 1-Year Est. Return
Envestnet Asset Management
Envestnet Asset Management Chicago, Illinois $424B AUM 22.96% 1-Year Est. Return
SRIM
Saratoga Research & Investment Management Saratoga, California $1.83B AUM 18.41% 1-Year Est. Return
MG
Markel Group Glen Allen, Virginia $13.1B AUM 15.62% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
OAM
Oppenheimer Asset Management New York $9.63B AUM 30.32% 1-Year Est. Return
Truist Financial
Truist Financial Charlotte, North Carolina $83.7B AUM 27.22% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $11.7B AUM 87.29% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return

Bank Hapoalim BM's NVO Position: Q2 2026 in Review

Bank Hapoalim BM increased its Novo Nordisk (NVO) stake by 2.9% in Q2 2026, buying an estimated $80.3K and bringing the position to 65,863 shares worth $3.16M. The position accounts for 0.21% of the portfolio, ranked #41.

Bank Hapoalim BM first reported a position in NVO in Q2 2017 and has held it in 37 quarters since. 768 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

  • Bank Hapoalim BM held 65,863 shares of Novo Nordisk worth $3.16M as of Q2 2026.
  • Bank Hapoalim BM bought 1,868 Novo Nordisk shares in Q2 2026, an estimated $80.3K.
  • Novo Nordisk made up 0.21% of Bank Hapoalim BM's portfolio in Q2 2026, its #41 holding.
  • Bank Hapoalim BM first reported a position in Novo Nordisk in Q2 2017 and has held it in 37 quarters since.
  • 768 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on Bank Hapoalim BM's 13F filing for Q2 2026, filed 5 Aug 2026.